Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exosome and MSC Injections for Salivary Gland Function in Primary Sjögren Syndrome
NCT07838454Phase 2Not yet recruiting
- Start
- Dec 2026
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Phase 2, randomised trial of endothelial progenitor cell-derived exosomes and mesenchymal stem cells in primary Sjögren syndrome (3 arms). Primary endpoint: Change in Salivary Flow Rate Assessed by Sialoscintigraphy at 6 months. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
endothelial progenitor cell-derived exosomesmesenchymal stem cells
03
Conditions
primary Sjögren syndrome
Beyond the preview
Go deeper on NCT07838454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07838454.